Philip Morris International Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. PMI manufactures and sells cigarettes and smoke-free products, including heated tobacco and oral nicotine products. In January 2024, it incorporated former Swedish Match results into its geographic segments; prior periods were reclassified for comparability.
Financial results and key metrics
| Metric | Q1 2024 | Q1 2023 / prior date | Change or context |
|---|---|---|---|
| Net revenues | $8.793 billion | $8.019 billion | +9.7% reported; +12.1% excluding currency |
| Gross profit / margin | $5.598 billion / 63.7% | $4.981 billion / 62.1% | Margin calculated from reported figures |
| Operating income / margin | $3.045 billion / 34.6% | $2.731 billion / 34.1% | +11.5% reported; +23.5% excluding currency |
| Net earnings attributable to PMI | $2.148 billion | $1.995 billion | +7.7% |
| Diluted EPS | $1.38 | $1.28 | +7.8%; +23.4% excluding unfavorable currency impact |
| Effective tax rate | 24.8% | 17.3% | Increase primarily reflected discrete deferred tax effects |
| Operating cash flow | $241 million | $(955) million | Improved, but remained modest relative to earnings |
| Capital expenditures | $417 million | $279 million | Primarily smoke-free manufacturing capacity |
| Cash and cash equivalents | $3.968 billion | $3.060 billion at Dec. 31, 2023 | Balance-sheet date comparison |
| Total debt | $50.4 billion | $47.9 billion at Dec. 31, 2023 | Increased; includes current and long-term debt |
Revenue mix and operating trends
- Smoke-free revenue was $3.386 billion, up 21.1%; smoke-free excluding Wellness and Healthcare rose 21.6% to $3.296 billion. Combustible tobacco revenue increased 3.5% to $5.407 billion.
- Shipment volumes: heated tobacco units rose 20.9%; oral products rose 40.0%, including nicotine pouch volume growth of 79.3%; cigarette shipments declined 0.4%.
- Regional revenue increased in Europe (+9.7%), SSEA, CIS & MEA (+7.3%), EA, AU & PMI Duty Free (+10.8%) and Americas (+14.7%). Americas operating income fell 45.9% to $99 million, reflecting higher impairment and exit costs, amortization and marketing and administration costs.
- Reported revenue and earnings faced unfavorable currency effects, especially from the Egyptian pound, Japanese yen and Russian ruble. Currency reduced diluted EPS by $0.20.
Cash, debt and liquidity
- Operating cash flow improved by $1.196 billion year over year. Management attributed the favorable underlying comparison mainly to approximately $1.0 billion lower working-capital requirements; cash use for receivables and other current liabilities remained significant. PMI also sold $2.7 billion of trade receivables during the quarter, with $701 million still outstanding at quarter-end.
- Investing cash outflow was $193 million. Financing cash inflow was $1.135 billion, including $4.659 billion of long-term debt proceeds and $2.037 billion of dividends paid.
- PMI issued $4.75 billion of U.S. dollar notes in February, with stated coupons from 4.750% to 5.250%. Short-term borrowings declined to $279 million from $1.968 billion at year-end, while long-term debt increased.
- At March 31, PMI had $6.2 billion of committed revolving credit facilities, all undrawn, and an $8.0 billion commercial paper program with $149 million outstanding. Credit ratings were Moody’s A2 stable, S&P A- stable and Fitch A negative.
- Quarterly dividends declared were $1.30 per share; the annualized rate was $5.20. PMI said it did not expect to restart share repurchases during 2024.
Outlook, commentary and material items
- 2024 outlook: operating cash flow of $10–$11 billion at prevailing exchange rates, subject to year-end working capital; capital expenditures of approximately $1.2 billion; total cigarette, heated tobacco and oral smoke-free shipment volume growth of flat to +1%; and U.S. nicotine pouch shipments of approximately 560 million cans.
- Management expects full-year 2024 effective tax rate of approximately 21%–22%, excluding discrete tax events. It expects international cigarette and heated tobacco industry volume, excluding China and the U.S., to range from a 2% decline to flat.
- PMI reacquires full U.S. IQOS commercialization rights from Altria effective May 1, 2024. The $2.7 billion consideration was paid by July 2023. PMI estimates incremental pre-tax amortization of about $370 million for the remaining eight months of 2024 and about $555 million annually for 2025–2028; final purchase accounting was to be completed after the rights transfer.
- Q1 asset impairment and exit costs were $168 million, including $121 million for restructuring IQOS U.S. sourcing and $47 million related to ceasing operations in Venezuela. PMI also recorded a $27 million intangible impairment, primarily for a Wellness and Healthcare in-process research and development project.
- Management cited pricing, higher HTU and ZYN volumes, and manufacturing and back-office efficiencies as drivers expected to continue supporting performance. Inflation, particularly wages and tobacco leaf costs, remains a cost headwind, although PMI expects a more moderate overall increase in 2024.
- Key risks include tobacco and nicotine regulation, excise taxes, illicit trade, competition, product adoption and FDA authorization, foreign exchange and capital controls, and geopolitical and supply-chain disruption. Russia and Ukraine remain material exposures; PMI reported approximately $2.6 billion of Russian assets, including $0.6 billion of cash mostly held in rubles, and approximately $0.5 billion of Ukrainian assets.
- Legal exposure includes tobacco litigation, Canadian proceedings stayed through September 30, 2024, and new U.S. ZYN-related claims. PMI reported no accrual for the cited new ZYN proceedings and said it could not estimate likelihood or loss range. The filing notes that certain litigation outcomes could materially affect results, cash flows or financial position; most pending combustible tobacco cases have no estimated loss accrued.
- A settlement with BAT resolved ongoing patent disputes and led to rescission of the U.S. ITC exclusion and cease-and-desist orders on March 11, 2024. Separately, the U.S. government asserted that PMI may need to submit to a 2006 court order before the Altria transaction; PMI said the government had not sought court relief and PMI believed the cited provision did not apply.
Important facts for investors to verify
- Whether smoke-free volume and revenue growth—particularly U.S. ZYN and IQOS—can be sustained, and whether planned ZYN capacity investments meet demand.
- Whether operating cash flow reaches the $10–$11 billion outlook, given working-capital movements, receivables sales and currency restrictions.
- How the IQOS U.S. rights transfer affects commercialization, regulatory status and actual amortization expense beginning May 2024.
- Developments in ZYN litigation, Canadian tobacco proceedings, the U.S. government’s position on the Altria transaction and the German heated-tobacco tax matter.
- Whether debt and interest costs, currency movements, tax-rate changes and Russia/Ukraine risks alter the outlook or PMI’s liquidity and earnings profile.